Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 505

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease

Open access
Park, Seung-Jung, Ahn, Jung-Min, Kim, Young-Hak, Park, Duk-Woo, Yun, Sung-Cheol, Lee, Jong-Young, Kang, Soo-Jin, Lee, Seung-Whan, Lee, Cheol Whan, Park, Seong-Wook, Choo, Suk Jung, Chung, Cheol Hyun, Lee, Jae Won, Cohen, David J., Yeung, Alan C., Hur, Seung Ho, Seung, Ki Bae, Ahn, Tae Hoon, Kwon, Hyuck Moon, Lim, Do-Sun, Rha, Seung-Woon, Jeong, Myung-Ho, Lee, Bong-Ki, Tresukosol, Damras, Fu, Guo Sheng, Ong, Tiong Kiam·2015·New England Journal of Medicine

Abstract

BACKGROUND: Most trials comparing percutaneous coronary intervention (PCI) with coronary-artery bypass grafting (CABG) have not made use of second-generation drug-eluting stents. METHODS: We conducted a randomized noninferiority trial at 27 centers in East Asia. We planned to randomly assign 1776 patients with multivessel coronary artery disease to PCI with everolimus-eluting stents or to CABG. The primary end point was a composite of death, myocardial infarction, or target-vessel revascularization at 2 years after randomization. Event rates during longer-term follow-up were also compared between groups. RESULTS: After the enrollment of 880 patients (438 patients randomly assigned to the PCI group and 442 randomly assigned to the CABG group), the study was terminated early owing to slow enrollment. At 2 years, the primary end point had occurred in 11.0% of the patients in the PCI group and in 7.9% of those in the CABG group (absolute risk difference, 3.1 percentage points; 95% confidence interval [CI], -0.8 to 6.9; P=0.32 for noninferiority). At longer-term follow-up (median, 4.6 years), the primary end point had occurred in 15.3% of the patients in the PCI group and in 10.6% of those in the CABG group (hazard ratio, 1.47; 95% CI, 1.01 to 2.13; P=0.04). No significant differences were seen between the two groups in the occurrence of a composite safety end point of death, myocardial infarction, or stroke. However, the rates of any repeat revascularization and spontaneous myocardial infarction were significantly higher after PCI than after CABG. CONCLUSIONS: Among patients with multivessel coronary artery disease, the rate of major adverse cardiovascular events was higher among those who had undergone PCI with the use of everolimus-eluting stents than among those who had undergone CABG. (Funded by CardioVascular Research Foundation and others; BEST ClinicalTrials.gov number, NCT00997828.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1415447

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 505

Metadata

Authors
Park, S.-J., Ahn, J.-M., Kim, Y.-H., Park, D.-W., Yun, S.-C., Lee, J.-Y., Kang, S.-J., Lee, S.-W., Lee, C. W., Park, S.-W., Choo, S. J., Chung, C. H., Lee, J. W., Cohen, D. J., Yeung, A. C., Hur, S. H., Seung, K. B., Ahn, T. H., Kwon, H. M., Lim, D.-S., Rha, S.-W., Jeong, M.-H., Lee, B.-K., Tresukosol, D., Fu, G. S., & Ong, T. K.
Venue
New England Journal of Medicine
Published
2015-03-26
Volume
372
Issue
13
Pages
1204-1212
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2105345588
Cited by
505
References
24
FWCI
54.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease. https://app.cochat.ai/papers/10.1056/nejmoa1415447
The paper
Park, S.-J., Ahn, J.-M., Kim, Y.-H., Park, D.-W., Yun, S.-C., Lee, J.-Y., Kang, S.-J., Lee, S.-W., Lee, C. W., Park, S.-W., Choo, S. J., Chung, C. H., Lee, J. W., Cohen, D. J., Yeung, A. C., Hur, S. H., Seung, K. B., Ahn, T. H., Kwon, H. M., . . . Ong, T. K. (2015). Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1415447

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.